These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38303927)

  • 41. Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy.
    Hu Y; Nie W; Lyu L; Zhang X; Wang W; Zhang Y; He S; Guo A; Liu F; Wang B; Qian Z; Gao X
    ACS Nano; 2024 Jan; 18(4):3295-3312. PubMed ID: 38252684
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CSF-1R inhibition disrupts the dialog between leukaemia cells and macrophages and delays leukaemia progression.
    Li K; Xu W; Lu K; Wen Y; Xin T; Shen Y; Lv X; Hu S; Jin R; Wu X
    J Cell Mol Med; 2020 Nov; 24(22):13115-13128. PubMed ID: 33037771
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CSF-1R in Cancer: More than a Myeloid Cell Receptor.
    Cersosimo F; Lonardi S; Ulivieri C; Martini P; Morrione A; Vermi W; Giordano A; Giurisato E
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254773
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.
    Quail DF; Bowman RL; Akkari L; Quick ML; Schuhmacher AJ; Huse JT; Holland EC; Sutton JC; Joyce JA
    Science; 2016 May; 352(6288):aad3018. PubMed ID: 27199435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications.
    Kumari A; Silakari O; Singh RK
    Biomed Pharmacother; 2018 Jul; 103():662-679. PubMed ID: 29679908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
    Shi G; Yang Q; Zhang Y; Jiang Q; Lin Y; Yang S; Wang H; Cheng L; Zhang X; Li Y; Wang Q; Liu Y; Wang Q; Zhang H; Su X; Dai L; Liu L; Zhang S; Li J; Li Z; Yang Y; Yu D; Wei Y; Deng H
    Mol Ther; 2019 Jan; 27(1):244-260. PubMed ID: 30527756
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor.
    Patsialou A; Wyckoff J; Wang Y; Goswami S; Stanley ER; Condeelis JS
    Cancer Res; 2009 Dec; 69(24):9498-506. PubMed ID: 19934330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer.
    Guan W; Hu J; Yang L; Tan P; Tang Z; West BL; Bollag G; Xu H; Wu L
    Endocr Relat Cancer; 2019 Jan; 26(1):131-140. PubMed ID: 30400004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1.
    Shih CT; Shiau CW; Chen YL; Chen LJ; Chao TI; Wang CY; Huang CY; Hung MH; Chen KF
    Cancer Lett; 2021 Feb; 498():142-151. PubMed ID: 33232786
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The possible mechanisms of tumor progression via CSF-1/CSF-1R pathway activation.
    Huang L; Xu X; Hao Y
    Rom J Morphol Embryol; 2014; 55(2 Suppl):501-6. PubMed ID: 25178319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment.
    Shi G; Shi P; Yu Y; Xu J; Ma J; Zhang Y; Dong Z; Shen L; Dai L; Cheng L; Cheng P; Deng H
    Mol Ther Oncolytics; 2021 Dec; 23():488-500. PubMed ID: 34901391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.
    Smith HO; Anderson PS; Kuo DY; Goldberg GL; DeVictoria CL; Boocock CA; Jones JG; Runowicz CD; Stanley ER; Pollard JW
    Clin Cancer Res; 1995 Mar; 1(3):313-25. PubMed ID: 9815987
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines.
    Morandi A; Barbetti V; Riverso M; Dello Sbarba P; Rovida E
    PLoS One; 2011; 6(11):e27450. PubMed ID: 22096574
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CSF-1R Inhibitor Development: Current Clinical Status.
    Peyraud F; Cousin S; Italiano A
    Curr Oncol Rep; 2017 Sep; 19(11):70. PubMed ID: 28875266
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor.
    Swierczak A; Cook AD; Lenzo JC; Restall CM; Doherty JP; Anderson RL; Hamilton JA
    Cancer Immunol Res; 2014 Aug; 2(8):765-76. PubMed ID: 25005824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia.
    Polk A; Lu Y; Wang T; Seymour E; Bailey NG; Singer JW; Boonstra PS; Lim MS; Malek S; Wilcox RA
    Clin Cancer Res; 2016 Dec; 22(24):6118-6128. PubMed ID: 27334834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas.
    Yan D; Kowal J; Akkari L; Schuhmacher AJ; Huse JT; West BL; Joyce JA
    Oncogene; 2017 Oct; 36(43):6049-6058. PubMed ID: 28759044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.
    Liao JB; Swensen RE; Ovenell KJ; Hitchcock-Bernhardt KM; Reichow JL; Apodaca MC; D'Amico L; Childs JS; Higgins DM; Buening BJ; Goff BA; Disis ML
    Gynecol Oncol; 2017 Mar; 144(3):480-485. PubMed ID: 28089377
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevance.
    Yadav S; Priya A; Borade DR; Agrawal-Rajput R
    Immunol Res; 2023 Apr; 71(2):130-152. PubMed ID: 36266603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.